ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Future Oncol
Κύριοι συγγραφείς: Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, Cortés, Javier
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Future Medicine Ltd 2019
Θέματα:
Clinical Trial Protocol
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7466911/
https://ncbi.nlm.nih.gov/pubmed/31074641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2019-0180
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια